GC
AMRI

Guggenheim Capital’s Albany Molecular Research Inc AMRI Stock Holding History

Guggenheim Capital’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-44,419
Closed -$966K – 2904
2017
Q2 		$966K Buy
+44,419
New +$806K ﹤0.01% 2099
2016
Q4 		– Sell
-86,850
Closed -$1.43M – 3045
2016
Q3 		$1.43M Sell
86,850
-11,229
-11% -$166K ﹤0.01% 1840
2016
Q2 		$1.32M Sell
98,079
-8,309
-8% -$121K ﹤0.01% 1851
2016
Q1 		$1.63M Sell
106,388
-33,401
-24% -$524K 0.01% 1718
2015
Q4 		$2.77M Buy
139,789
+691
+0.5% +$13.1K 0.01% 1379
2015
Q3 		$2.42M Sell
139,098
-1,159
-0.8% -$23.6K 0.01% 1462
2015
Q2 		$2.84M Buy
140,257
+23,501
+20% +$454K 0.01% 1500
2015
Q1 		$2.06M Buy
116,756
+21,913
+23% +$373K ﹤0.01% 1748
2014
Q4 		$1.54M Buy
94,843
+2,479
+3% +$45.5K ﹤0.01% 1932
2014
Q3 		$2.04M Sell
92,364
-21,902
-19% -$448K ﹤0.01% 1759
2014
Q2 		$2.3M Sell
114,266
-22,369
-16% -$379K 0.01% 1691
2014
Q1 		$2.54M Sell
136,635
-57,024
-29% -$785K 0.01% 1588
2013
Q4 		$1.95M Buy
+193,659
New +$2.34M 0.01% 1813

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Guggenheim Capital's AMRI Position: Q3 2017 in Review

Guggenheim Capital sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 44,419 shares — an estimated $966K sold.

Guggenheim Capital first reported a position in AMRI in Q4 2013 and held it in 13 quarters. The position peaked at $2.84M in Q2 2015. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Guggenheim Capital reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Guggenheim Capital sold 44,419 Albany Molecular Research Inc shares in Q3 2017, an estimated $966K.
  • Guggenheim Capital first reported a position in Albany Molecular Research Inc in Q4 2013 and held it in 13 quarters.
  • Guggenheim Capital's Albany Molecular Research Inc position peaked at $2.84M in Q2 2015.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Guggenheim Capital's 13F filing for Q3 2017, filed 14 Nov 2017.